STTR Phase I: Nanoshell-Based Cancer Therapy

这个小企业技术转让（STTR）第一阶段将开发一种新的，基于纳米技术的癌症疗法。 这种疗法，基于纳米壳的热消融（NBTA），有望成为一种重要的新治疗工具，用于治疗手术伴随高发病率或死亡率的不可手术的癌症或肿瘤。 该疗法将利用专有的纳米壳将外部施加的近红外（nIR）光转化为局部热量，以破坏靶向癌细胞，最大限度地减少对周围组织的损伤，并避免放射治疗或化疗的长期影响。 该STTR项目的具体目标包括（i）了解纳米壳的生物分布和清除，（ii）了解纳米壳的肿瘤摄取，以及（iii）评估用纳米壳治疗的癌症动物的存活时间。该项目的商业应用将在癌症治疗中。 NBTA将导致由纳米壳和光传输系统（激光）组成的FDA监管设备。该公司将与一家激光制造商以及一家营销和销售合作伙伴合作，分销该产品。

This Small Business Technology Transfer (STTR) Phase I will develop a novel, nanotechnology-based cancer therapy. This therapy, nanoshell-based thermal ablation (NBTA), holds the promise as a significant new therapeutic tool for the treatment of otherwise inoperable cancers or neoplasms where surgery is accompanied by a high probability of morbidity or mortality. The therapy will utilize proprietary nanoshells to convert externally applied near-infrared (nIR) light into localized heat to destroy targeted cancer cells, minimizing damage to surrounding tissue and avoiding the long-term effects of radiation therapy or chemotherapy. Specific goals of this STTR project include (i) understanding biodistribution and clearance of nanoshells, (ii) understanding tumor uptake of nanoshells, and (iii) assessment of the survival time of animals with cancers that have been treated with nanoshells.The commercial application of this project will be in cancer therapy. NBTA will lead to an FDA regulated device comprised of nanoshells and a light delivery system (laser). The company will partner with a laser manufacturer, and with a marketing and sales partner, for distribution of the product.